Efter aflæggelse af Q3 regnskabet afholdte Coloplast ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Coloplast indleder præsentationen sådan:
Q3 Highlights
Negative organic growth of -2% and -4% reported decline in DKK
• Chronic Care delivered a stable underlying growth in Q3, adversely
impacted by the reversal of the majority of the positive DKK ~150m
impact from the previous stock building
• Interventional Urology reported -40% in Q3 due to decline in elective
procedures in primarily the US. Performance improved during Q3 with
April, May and June down 70%, 45%, 3% respectively
• In Q3, Wound and Skin Care delivered -6% organic primarily due to a
decline in hospital procedures resulting in lower sales in China, Europe
and US Skin Care
• EBIT declined 5% to DKK 1,368m negatively impacted by the drop in
revenue and despite cost saving initiatives but also reflecting sustained
investments in growth opportunities and innovation as well as IT
• ROIC after tax before special items(1) of 40%
• Financial guidance for 2019/20 narrowed:
• Organic revenue growth of ~4% from previously 4-6% and a
reported growth in DKK of 3-4% from previously 4-6% due to
weaker outlook for Wound & Skin Care and UK Chronic Care
• EBIT margin of ~31% from previously 30-31% in constant exchange
rates and in reported EBIT margin in DKK of ~31% from previously
30-31%
• Capex of DKK 950m
